Angeles Wealth Management LLC Raises Stake in Insulet Co. (NASDAQ:PODD)

Angeles Wealth Management LLC grew its holdings in Insulet Co. (NASDAQ:PODD) by 6.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,314 shares of the medical instruments supplier’s stock after acquiring an additional 79 shares during the quarter. Angeles Wealth Management LLC’s holdings in Insulet were worth $343,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in PODD. Integrated Wealth Concepts LLC raised its stake in Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after acquiring an additional 42 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after purchasing an additional 43 shares during the period. Glenmede Trust Co. NA increased its holdings in shares of Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after purchasing an additional 47 shares during the period. Graypoint LLC raised its stake in shares of Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of Insulet by 9.6% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 47 shares during the period.

Insider Activity

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Barclays boosted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. BTIG Research increased their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Canaccord Genuity Group raised their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Citigroup boosted their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $277.13.

Insulet Price Performance

Shares of NASDAQ PODD opened at $285.34 on Tuesday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market cap of $20.01 billion, a price-to-earnings ratio of 48.86, a PEG ratio of 3.61 and a beta of 1.23. The company’s 50-day moving average price is $270.65 and its 200 day moving average price is $242.24. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.